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Abstract
Background: Myogenic differentiation involves cell-cycle arrest, activation of the muscle-specific transcriptome, and
elongation, alignment and fusion of myoblasts into multinucleated myotubes. This process is controlled by
promyogenic transcription factors and regulated by signaling pathways in response to extracellular cues. The p38
mitogen-activated protein kinase (p38 MAPK) pathway promotes the activity of several such transcription factors,
including MyoD and MEF2, thereby controlling the muscle-specific transcription program. However, few p38-
regulated genes that play a role in the regulation of myogenesis have been identified.
Methods: RNA interference (RNAi), chemical inhibition and immunofluorescence approaches were used to assess
the role of drebrin in differentiation of primary mouse myoblasts and C2C12 cells.
Results: In a search for p38-regulated genes that promote myogenic differentiation, we identified Dbn1, which
encodes the actin-binding protein drebrin. Drebrin is an F-actin side-binding protein that remodels actin to
facilitate the change of filopodia into dendritic spines during synaptogenesis in developing neurons. Dbn1 mRNA
and protein are induced during differentiation of primary mouse and C2C12 myoblasts, and induction is
substantially reduced by the p38 MAPK inhibitor SB203580. Primary myoblasts and C2C12 cells depleted of drebrin
by RNAi display reduced levels of myogenin and myosin heavy chain and form multinucleated myotubes very
inefficiently. Treatment of myoblasts with BTP2, a small-molecule inhibitor of drebrin, produces a phenotype similar
to that produced by knockdown of drebrin, and the inhibitory effects of BTP2 are rescued by expression of a
mutant form of drebrin that is unable to bind BTP2. Drebrin in myoblasts is enriched in cellular projections and cell
cortices and at regions of cell-cell contact, all sites where F-actin, too, was concentrated.
Conclusions: Our findings reveal that Dbn1 expression is a target of p38 MAPK signaling during myogenesis and
that drebrin promotes myoblast differentiation.
Keywords: myoblast, cell differentiation, drebrin, myotube, actin
Background
Myoblast differentiation is a multistep process that
involves withdrawal from the cell cycle, acquisition of a
cell type-specific transcriptional program and morpholo-
gical changes that include elongation, alignment and
fusion of myoblasts to form myofibers [1-4]. Whereas
transcriptional regulation is at the core of myogenesis,
the formation and growth of myofibers is also controlled
by a variety of signaling ligands and their receptors,
including insulin-like growth factor 1, fibroblast growth
factors (FGFs), Wnts, transforming growth factor b
superfamily members and others [1-3,5]. Furthermore,
the activity of MyoD and other promyogenic transcrip-
tion factors is tightly controlled at the posttranslational
level by signal transduction pathways, including phos-
phatidylinositol 3-kinase/Akt, integrin/focal adhesion
kinase (FAK) and calcium/calcineurin [4,6-9]. Among
the signaling pathways that promote myogenesis, the
p38a/b MAPK (p38a/b mitogen-activated protein
kinase) pathway plays a prominent role. There is a per-
sistent rise in p38a/b (hereafter simply “p38”) activity
during myoblast differentiation, and inhibition of p38
expression or activity blocks induction of select muscle-
specific genes and myogenic differentiation [8,10-13].
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gene expression at several levels, including MyoD dimeri-
zation with E proteins, Mef2 transcriptional activity,
chromatin remodeling at muscle-specific genes and stabi-
lity of myogenic mRNAs [11,13-18]. Despite progress in
understanding these proximal targets of p38’sp r o m y o -
genic actions, few p38-regulated genes that play a role in
the regulation of myogenesis have been identified.
In addition to the acquisition of a muscle-specific tran-
scriptional program, the changes in myoblast morphology
that occur during differentiation indicate that dramatic
alterations in the F-actin cytoskeleton are required for the
formation of myofibers. Consistent with this notion, lamel-
lipodia and filopodia, cellular structures that require actin
remodeling, form dynamically during myoblast differentia-
tion in vitro [19-21]. Furthermore, disruption of the F-
actin cytoskeleton by chemical or other means inhibits
various aspects of myoblast differentiation, including myo-
blast fusion [21-24]. At least some aspects of the cytoskele-
tal rearrangement and morphological changes that occur
during differentiation are likely to be mediated by tran-
scriptional induction of regulators of these processes, as
expression of MyoD in fibroblasts induces not only
expression of muscle-specific genes but also elongation
and fusion into multinucleated myotubes [4].
Drebrin is a ubiquitously expressed F-actin side-bind-
ing protein that is highly abundant in the brain [25,26].
Drebrin contains an actin-depolymerizing factor II/cofi-
lin-like domain, an actin-binding domain and two
Homer-binding domains [27], and it remodels actin to
facilitate the maturation of filopodia into dendritic
spines during synaptogenesis in developing neurons (for
reviews, see [27,28]). It is localized in lamellipodia and
filopodia, at sites of cell-cell contact and in adhesion
plaques [27-32]. Furthermore, drebrin associates with
several proteins that promote myoblast differentiation
and/or fusion, including the microtubule plus-tip bind-
ing protein EB3 [33,34]; the scaffold protein Homer
[35,36] and, via Homer, the small GTPase Cdc42
[35,37,38]; and the chemokine receptor CXCR4 [39,40].
We report herein that drebrin expression is induced
during differentiation of primary and C2C12 myoblasts
in a p38 MAPK-dependent manner. Furthermore, deple-
tion of drebrin by RNA interference (RNAi) or inhibi-
tion of its function with a small-molecule antagonist
diminished expression of muscle-specific genes and
myotube formation. Drebrin is therefore an actin-regu-
lating factor induced during myogenic differentiation
that promotes the differentiation process.
Methods
Cell culture
Primary myoblasts were isolated from wild-type mice at
postnatal day 13 by the method of Rando and Blau [41]
and maintained as previously described [42]. Differentia-
tion was induced by switching cultures from Ham’s F-10
medium with 20% fetal bovine serum (FBS)/2.5 ng/ml
basic FGF (R&D Systems, Minneapolis, MN, USA)/4%
penicillin-streptomycin (growth medium (GM)) to
DMEM with 5% horse serum (differentiation medium
(DM)). C2C12 myoblasts were maintained in DMEM
containing 15% FBS supplemented with 1% penicillin/
streptomycin and L-glutamine (GM). Differentiation was
induced by transferring to DMEM supplemented with
2% horse serum (DM). Where indicated, 5 μM
SB203580 (Sigma-Aldrich, St Louis, MO, USA) or 5 μM
BTP2 (Calbiochem, La Jolla, CA, USA) were added to
cultures and replenished every 12 hours.
Expression of drebrin
Plasmids encoding murine GFP-tagged drebrin E were
generated by subcloning cDNA encoding either wild-
type murine Dbn1 E or the K270M, K271M mutant into
the pEGFP-C1 vector (Clontech Laboratories, Inc,
Mountain View, CA, USA). Plasmids were transfected
into C2C12 cells using Lipofectamine 2000 reagent
(Invitrogen/Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s instructions.
RNAi
For small hairpin RNA studies, four sequences against
murine Dbn1 were initially chosen. The oligonucleotides
were cloned into the pSUPER.puro vector (Oligoengine,
Seattle, WA, USA) and transfected into C2C12 cells
with Lipofectamine 2000 reagent. Puromycin-resistant
cells were selected, pooled and examined by Western
blot analysis for drebrin expression. The most effective
sequences were chosen for further studies and corre-
sponded to nucleotides 5’ GCCACTTCGAGAACCA-
GAAAG 3’ (siDbn1-1) and 5’ AGGAAGAGCCATGT
GCAAAGGT 3’ (siDbn1-3) (NM_019813.3).
Twenty-four hours after selection, cultures were
seeded onto growth factor-reduced Matrigel (R&D Sys-
tems)-coated dishes at a density of 150,000 cells/ml.
Twenty-four hours later, cultures were switched to DM.
At various time points later, cultures were fixed with 2%
paraformaldehyde (PFA) and immunostained for myosin
heavy chain (MHC) and drebrin expression. Sister cul-
tures were lysed, and 30 μg of cleared cell extracts were
examined by Western blot analysis as previously
described [43]. Drebrin expression was also knocked
down by transfection of C2C12 cells or primary myo-
blasts with 200 nM drebrin-specific RNAi (4390771;
Ambion/Life Technologies) or with 200 nM control
nonsilencing RNAi Red (465318; Invitrogen/Life Tech-
nologies). RNAs were transfected with StemPro Lipo-
Max reagent (Invitrogen/Life Technologies) according to
the manufacturer’s instructions. Thirty-six hours after
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expression by Western blot analysis or analyzed for dif-
ferentiation potential tested by transfer to DM.
Protein analysis
Western blot analyses were performed as described in
Kang et al. [43]. Briefly, cells were lysed in extraction
b u f f e r( 5 0m MT r i s · H C l ,p H7 . 4 ,5 0m MN a F ,5m M
sodium pyrophosphate, 1 mM sodium orthovanadate, 1
mM ethylenediaminetetraacetic acid, 1% Triton X-100)
supplemented with protease and phosphatase inhibitor
cocktail (Sigma-Aldrich). Total proteins were resolved
on SDS-polyacrylamide gels, transferred onto Immobi-
lon polyvinylidene fluoride membranes (Millipore, Biller-
ica, MA, USA) and probed with specific antibodies.
Primary antibodies used were anti-drebrin (Abcam,
Cambridge, MA, USA), anti-tubulin (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), anti-myogenin (F5D;
Santa Cruz Biotechnology) and anti-MHC (MF20;
Developmental Studies Hybridoma Bank, Department of
Biology, University of Iowa, Iowa City, IA, USA). Mem-
branes were reprobed with the appropriate horseradish
peroxidase-conjugated secondary antibody (The Jackson
Laboratory, Bar Harbor, ME, USA), and specific bands
were visualized with an enhanced chemiluminescence
detection system (Roche Applied Science, Indianapolis,
IN, USA)
RNA analysis
RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Valencia, CA, USA). One microgram of total RNA was
reverse-transcribed using the First-Strand cDNA Synth-
esis Kit (Invitrogen/Life Technologies). One-tenth of the
cDNA was applied for real-time PCR using QuantiFast
SYBR Green RT-PCR Kit (QIAGEN) and analyzed on a
Bio-Rad Q5 cycler (Bio-Rad Laboratories, Hercules, CA,
USA).
Dbn1, Myh3, Myog and Gapdh mRNA expression
were quantified with the following primers. Dbn1 for-
ward: 5’ AGGCCAAGAAGGAGGAAGAG 3’; Dbn1
reverse: 5’ TTCCTCCTGTGCTCCTCAAT 3’; Myh3
forward: 5’ CAGAAATGGAGACACGGATCAGA 3’;
Myh3 reverse: 5’ AGAGGTGAAGTCACGGGTCTT
TGCC 3’; Myog forward: 5’GGGCCCCTGGAA
GAAAAG 3’; Myog reverse: 5’AGGAGGCGCTGTGG-
GAGT 3’; Gapdh forward: 5’ TGCACCACCAACTGC
TTA 3’; Gapdh reverse: 5’ GATGCAGGGATGA
TGTTC 3’.
Immunostaining and microscopy
Cells were grown on either Matrigel- or collagen-coated
dishes as indicated, fixed with 2% PFA for 10 minutes,
permeabilized with 0.1% Triton X-100 for 5 minutes,
blocked with PBS containing 5% goat serum for 1 hour
and incubated overnight with the following primary
antibodies: anti-MHC (clone MF-20; Developmental
Studies Hybridoma Bank), anti-drebrin (rabbit; Abnova,
Walnut, CA, USA) and Alexa Fluor 568 phalloidin (Invi-
trogen/Life Technologies). After being washed three
times with PBS, cells were incubated with the appropri-
ate secondary antibody conjugated with Alexa Fluor 488
or 568 (Invitrogen/Life Technologies) for 1 hour, coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI)
and then visualized using a Nikon Eclipse TS100
inverted microscope (Nikon Instruments, Melville, NY,
USA). Images were acquired using a ProgRes digital
microscope camera system and software (Jenoptik AG,
Jena, Germany).
Cell proliferation and cell death assays
Cell proliferation was assessed by bromodeoxyuridine
(BrdU) incorporation as described by Kang et al. [44].
Briefly, dividing cells were incubated in 20 mM BrdU
for 2 hours. The medium was aspirated, and cells were
immediately fixed for 30 minutes at -20°C with ice-cold
70% ethanol/30% glycine at pH 2.0. After being washed
with PBS, cells were incubated with mouse anti-BrdU
(Chemicon International/Millipore, Temecula, CA, USA)
and anti-mouse Alexa Fluor 568 (Invitrogen/Life Tech-
nologies). Cells were counterstained with DAPI and
visualized by the standard immunofluorescence protocol.
Apoptosis was analyzed with the In Situ Cell Death
Detection Kit (Roche Applied Science) according to the
manufacturer’s instructions.
Results
Dbn1 is induced during myogenic differentiation
In an effort to identify genes regulated by p38 signal-
ing during myoblast differentiation, microarray ana-
lyses were performed on C2C12 cells cultured at low
density in GM or DM at various time points, plus or
minus the p38 inhibitor SB203580. Details of the
screen will be published elsewhere. Herein we describe
studies of one such gene identified in this screen,
Dbn1, which encodes drebrin. Quantitative RT-PCR
(qRT-PCR) analysis revealed that Dbn1 is expressed at
very low levels in proliferating primary myoblasts in
GM, is expressed at higher levels at the time of shift
to DM (day 0, when cells have reached near-conflu-
ence) and increases in abundance over the next 2 days
in DM (Figure 1A). Analysis of Myog and Myh3
expression served as a positive control for differentia-
tion. Dbn1 expression during myoblast differentiation
was biphasic, as mRNA levels decreased again after 3
days in DM. Parallel cultures treated with SB203580
displayed strongly dampened induction of Dbn1, Myog
and Myh3 expression over this time course (Figure
1A). There are two alternatively spliced isoforms of
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E, which lacks this exon and is expressed broadly
[27,28]. qRT-PCR with pan-drebrin or drebrin A-speci-
fic primers revealed, as expected, that drebrin E is the
isoform expressed in myoblasts (data not shown).
Drebrin protein levels in differentiating cultures of pri-
mary myoblasts and C2C12 cells were regulated simi-
larly to Dbn1 mRNA in that they were induced during
differentiation in an SB203580-sensitive manner,
except that drebrin protein levels did not decrease
after 3 days in DM; rather, they were still at their peak
at this time point (Figures 1B and 1C). These results
suggest that drebrin protein may be more stable than
the mRNA that encodes it. In some Western blots, two
distinct drebrin bands were resolved (e.g., Figure 1C).
Treatment of cell lysates with alkaline phosphatase led
to loss of the more slowly migrating band but had no
effect on the mobility of the lower band, indicating
that the upper band, as reported previously [45], is a
phosphorylated form of drebrin (data not shown). The
ratios of the two bands did not change as drebrin pro-
tein levels rose during differentiation, suggesting that
phosphorylation is not a differentiation-dependent or
regulated event.
RNAi-mediated depletion of drebrin inhibits myoblast
differentiation and myotube formation
To explore a role for drebrin in myogenesis, an RNAi
approach was taken. Two independent Dbn1 sequences
were placed into the pSuper.puro vector and were indi-
vidually and stably expressed in C2C12 cells. A vector
harboring an irrelevant sequence was used as a control.
Induction of drebrin was substantially dampened during
differentiation of C2C12 cells that expressed either
siRNA sequence, relative to control transfectants (Figure
2C). Depletion of drebrin with either sequence resulted
in a similar strong reduction in the formation of multi-
nucleated myotubes. Whereas control cells formed large
myotubes, the majority of which had more than 20
nuclei, drebrin-depleted cells formed thin myotubes
with fewer than five nuclei (Figures 2A and 2B). Produc-
tion of the differentiation markers myogenin and MHC
was somewhat variably affected in these cell lines, but
each accumulated lower amounts of these muscle-speci-
fic proteins than did control transfectants during 3 days
in DM (Figure 2C). To explore this further, we directly
transfected siRNAs corresponding to a third Dbn1
sequence into both C2C12 cells and primary myoblasts.
In both cell types, drebrin protein was barely detectable
Figure 1 Dbn1 is upregulated during myoblast differentiation in an SB203580-sensitive manner. (A) Primary mouse myoblasts
proliferating in growth medium (G) or transferred to differentiation medium for the indicated times in the presence (+) or absence (-) of 5 μM
SB203580 were analyzed by quantitative RT-PCR for expression Dbn1, Myog (encoding myogenin) and Myh3 (encoding myosin heavy chain 3;
MHC3). (B) Cultures parallel to those in part (A) were examined by Western blot analysis for drebrin, myogenin and MHC production. Tubulin
was used as a loading control. (C) C2C12 myoblasts were analyzed similarly to the primary myoblasts shown in part (B).
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of myogenin and MHC in these cultures was observed
by Western blotting and immunofluorescence, but was
diminished relative to control cultures (Figures 3A, C, D
and 3F). Formation of multinucleated myotubes was
strongly inhibited in both C2C12 and primary myoblasts
by anti-Dbn1 siRNA (Figures 3A, B, D and 3E). Taken
together, these results indicate that drebrin promotes
myoblast differentiation, as assessed by both biochemical
and morphological criteria.
The possibility that defective differentiation of myo-
blasts depleted of drebrin was due to alterations in cell
proliferation or apoptosis was examined by measuring
BrdU incorporation and by terminal deoxynucleotidyl-
transferase deoxyuridine triphosphate nick-end labeling
(TUNEL) assay, respectively. BrdU incorporation was
slightly, but significantly, increased in primary myoblasts
in GM treated with anti-Dbn1 siRNA relative to control
cells (Figure 4A). Approximately 2% of cells in control
cultures in GM were TUNEL-positive, and this was
increased to about 5% in drebrin-depleted cultures (Fig-
ure 4B). Forty-eight hours after switching to DM, about
8% of cells in the control cultures were TUNEL-positive,
whereas approximately 15% of cells in drebrin-depleted
cultures were undergoing apoptosis (Figure 4B).
Although these increases in cell proliferation and apop-
tosis may contribute to the defective myogenesis seen in
cells depleted of drebrin, they are insufficient to explain
the quantitatively much stronger effects on myotube
formation.
The drebrin inhibitor BTP2 blocks myoblast
differentiation and myotube formation
BTP2 is a 3,5-bis(trifluoromethyl)pyrazole derivative that
binds directly to drebrin and blocks actin rearrange-
ments induced by forced expression of drebrin in CHO
cells [46,47]. We treated C2C12 cells and primary myo-
blasts with BTP2 to assess its effects on formation of
myotubes and expression of myogenin and MHC. In
both primary myoblasts and C2C12 cells, treatment with
BTP2 throughout a 3-day differentiation time course
resulted in formation of myotubes with much fewer
nuclei than those formed by vehicle-treated cells (Fig-
ures 5A, B, D and 5E). Expression of myogenin and
MHC was also diminished by BTP2 (Figures 5C and
5F). Therefore, treatment of myoblasts with BTP2 pro-
duced a phenotype similar to knockdown of drebrin,
although BTP2 did not alter drebrin protein levels (Fig-
ures 5C and 5F).
To prove that drebrin was the target of BTP2 that led
to inhibition of myogenesis, C2C12 cells were stably
transfected with expression vectors encoding either wild-
type drebrin E fused to GFP or a mutant form of drebrin
E that cannot bind BTP2(K270M, K271M) [46], also
fused to GFP. A vector that expressed GFP alone was
used as an additional control. Western blot analyses with
antibodies to drebrin showed that the levels of drebrin E-
GFP and drebrin E(K270M, K271M)-GFP were very simi-
lar to each other and to the levels of endogenously
expressed drebrin (Figure 6A). As expected, GFP-expres-
sing cells formed myotubes efficiently in a manner that
was inhibited by treatment with BTP2 (Figures 6B and
6C). Expression of drebrin E-GFP had only a very modest
ability to rescue the inhibitory effects of BTP2 (Figures
6B and 6C), suggesting that the concentration of the
drug used was sufficient to inhibit the approximately
twofold increase in overall drebrin levels in these cells. In
contrast, expression of drebrin E(K270M, K271M)-GFP
strongly rescued the fusion index of BTP2-treated cells to
near that of untreated cells (Figures 6B and 6C). These
results indicate that the major target of BTP2 in the inhi-
bition of myogenesis is drebrin.
To gain further insight into drebrin function, 5-day
(120 hours) differentiation time courses were performed
Figure 2 RNA interference (RNAi)-mediated depletion of
drebrin reduces C2C12 cell differentiation. (A) C2C12 cells were
transfected with either pSUPER (control) or pSUPER containing RNAi
sequences targeted against Dbn1 (siDbn1-1, siDbn1-3). After 3 days
in differentiation medium (DM), cultures were fixed and double-
stained for myosin heavy chain (red) and 4’,6-diamidino-2-
phenylindole (blue). Bar: 0.1 mm. (B) Quantification of myotube
formation. Values shown are means ± SD of triplicate
determinations. *P < 0.05. (C) Western blot analysis of C2C12 cells
expressing the indicated control or Dbn1 siRNA vectors cultured in
growth medium (G) or DM for the indicated times.
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the cultures continuously from the time of switch to
DM (designated as time 0), (2) BTP2 was added to cul-
tures after 60 hours in DM without BTP2 and was
maintained until the final 120-hour time point or (3)
DMSO was present in the cultures as a vehicle control
throughout the entire 120-hour time course (see Figure
7A). Cells were harvested at 72 and 120 hours for analy-
sis of myotube formation and production of myogenin
and MHC. Relative to DMSO vehicle controls, cells
treated with BTP2 throughout the time course (condi-
tion 1) displayed a reduced overall fusion index, smaller
myotubes with fewer nuclei and lower levels of myo-
genin and MHC at both 72 and 120 hours (Figures 7B
through 7E). The number of nuclei per myotube, and
levels of MHC, increased between 72 and 120 hours in
DM in both control cultures and cultures continuously
treated with BTP2, but the latter cultures differentiated
defectively by these measures at both time points,
relative to control cells at the same time point (Figures
7B and 7E). In contrast to the effects seen with cells
treated continuously with BTP2, cultures in which BTP2
treatment began at 60 hours were indistinguishable
from DMSO control cultures when analyzed at 120
hours. Levels of MHC (but not myogenin) increased in
control cultures between 72 and 120 hours, but this
increase was unaffected when BTP2 was added at the
60-hour time point (Figure 7B). Similarly, the number of
nuclei per myotube increased significantly between 72
and 120 hours in control cultures, and myotubes with
very large numbers of nuclei formed during this period;
h o w e v e r ,i n c l u s i o no fB T P 2a t6 0h o u r sh a dn oe f f e c t
on this process (Figures 7C through 7E). The overall
fusion index of control cultures did not increase
between 72 and 120 hours, so the increase in nuclei per
myotube at 120 hours presumably reflects myotube-
myotube fusion. The results shown in Figure 7 reveal
that drebrin functions to promote myogenesis relatively
Figure 3 siRNA-mediated depletion of drebrin inhibits differentiation of primary myoblasts. (A) C2C12 cells were transfected with
nonsilencing (control) or Dbn1-specific siRNA. After 3 days in differentiation medium, cultures were fixed and triple-stained for myosin heavy
chain (MHC; red), drebrin (green) and 4’,6-diamidino-2-phenylindole (blue). Bar: 20 μM. (B) Quantification of fusion index in cultures from part
(A). Con, control siRNA. Values shown are means ± SD of triplicate determinations. *P < 0.01. (C) Cultures parallel to those in part (A) were
examined by Western blot analysis for drebrin, myogenin and MHC production. Tubulin was used as a loading control. (D) through (F) are the
same as parts (A) through (C), except primary myoblasts were used.
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sable in a later phase characterized by increased levels
of MHC and myotube-myotube fusion.
Drebrin localization
We determined drebrin’s subcellular localization during
differentiation of C2C12 myoblasts by immunofluores-
cence. Although drebrin levels are relatively low in low-
density cultures in GM (Figure 1), drebrin was concen-
trated in cell projections and at cell cortices, areas that
also accumulated F-actin, as revealed by costaining with
phalloidin (Figure 8A). A similar result was obtained by
direct visualization of drebrin E-GFP transiently
expressed in C2C12 cells (Figure 8C). In higher-density
cultures in DM for 24 hours (a condition in which such
cells are preparing to fuse), drebrin was somewhat diffu-
sely distributed in the cytoplasm but was concentrated
at sites of cell-cell contact (Figure 8A). In myotubes
after 3 days in DM, drebrin was again concentrated at
sites of cell contact between myotubes and also at the
tips of myotubes (Figure 8B).
Discussion
Myoblast differentiation involves expression of the mus-
cle-specific transcriptional program and changes in cel-
lular morphology, most strikingly among the latter,
fusion into multinucleated myofibers. The p38 MAPK
signaling pathway promotes myogenic differentiation,
including myoblast fusion [6,8]. The reported substrates
of p38 that are involved in myogenesis are all involved
with expression of muscle-specific genes [11-14,16-18],
yet few p38 target genes that regulate myogenesis have
been identified. In this report, we identify Dbn1, encod-
ing drebrin, as a gene that is induced during myoblast
differentiation in an SB203580-sensitive manner and
that promotes the differentiation process.
The inhibition of Dbn1 induction by SB203580 sug-
gests that one or more p38-regulated transcription fac-
tors are involved, directly or indirectly, in the expression
of Dbn1 during myoblast differentiation. MyoD and
Mef2 family members are well-established as p38-regu-
lated transcription factors that are central to muscle-
specific gene expression and myogenesis, and they are
therefore potential candidate regulators of Dbn1 expres-
sion [8]. Investigators in a recent study identified
MEK5/ERK5 as a signaling pathway in myoblasts that
induces expression of the transcription factors Klf2 and
Klf4. Klf2 and Klf4 in turn regulate a set of target genes
involved in myoblast fusion, largely independently of
MyoD and Mef2, and Dbn1 was among this set of ERK5
® Klf2/Klf4 target genes [48]. Klf4 can be posttransla-
tionally activated by p38 MAPK [49], providing another
potential explanation for the sensitivity of Dbn1 induc-
tion to SB203580. The nonreceptor tyrosine kinase FAK
is important for myoblast maturation and fusion, and
Dbn1 induction failed to occur properly in primary
myoblasts in which fusion was inhibited by forced
expression of FAT (Focal Adhesion Targeting, a natu-
rally occurring dominant-negative variant of FAK) (see
Table S1 in [9]). Taken together, Dbn1 expression has
been associated with myogenesis in several systems, but
its regulation is likely to be complex, integrating input
from multiple signaling pathways and, potentially, multi-
ple transcription factors.
RNAi-mediated depletion of drebrin or inhibition of
drebrin function with the chemical inhibitor BTP2 led
to decreases in expression of myogenin and MHC and
inhibition of myotube formation. Drebrin encodes an F-
actin side-binding protein and is best known for its role
in remodeling actin to promote maturation of filopodia
into dendritic spines during synaptogenesis in develop-
ing neurons [27,28]. Production and remodeling of F-
actin-enriched structures is a key event in myoblast
fusion [50], and it is logical to posit that drebrin may
participate in such events. However, the fact that
Figure 4 Cell proliferation and apoptosis in primary myoblasts
depleted of drebrin. (A) Primary myoblatsts were transfected with
control or Dbn1-specific siRNA. Cells were cultured for 36 hours in
growth medium (GM), then exposed to bromodeoxyuridine (BrdU)
for 2 hours and finally fixed and stained with antibody against BrdU.
Values shown are means ± SD of triplicate determinations. (B)
Primary myoblasts were transfected with control (Con) or Dbn1-
specific siRNA. Cells were cultured in GM for 36 hours or in
differentiation medium for 48 hours. Values shown are means ± SD
of triplicate determinations. *P < 0.01 by Student’s t-test.
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72 hours in the presence or absence of the drebrin inhibitor BTP2 (5 μM), then fixed and stained for myosin heavy chain (MHC) (red) and
drebrin (green). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (blue). (B) Quantification of the fusion index in cultures from part
(A). Values shown are means ± SD of triplicate determinations. *P < 0.01. (C) Cultures parallel to those in part (A) were examined by Western
blot analysis for drebrin, myogenin and MHC production. Tubulin was used as a loading control. (D) through (F) are the same as (A) through
(C), except C2C12 cells were used. The asterisks in (E) refer to differences between dimethyl sulfoxide- and BTP2-treated cells in each of the
indicated categories.
Mancini et al. Skeletal Muscle 2011, 1:36
http://www.skeletalmusclejournal.com/content/1/1/36
Page 8 of 13depletion or chemical inhibition of drebrin reduced the
levels of myogenin, which is itself required for differen-
tiation, raises the possibility that the diminished fusion
into myotubes seen upon loss of drebrin function may
occur as a consequence of a more generalized block in
differentiation due to suboptimal myogenin induction.
The decrease in MHC expression seen in drebrin-inhib-
ited cells and the fact that, based on time courses of
Figure 6 Expression of a drebrin mutant insensitive to BTP2 rescues myotube formation in BTP2-treated C2C12 cells. (A) C2C12 cells
were transfected with vectors encoding GFP, drebrin E-GFP or drebrin E (K270M, K271M)-GFP. Transfection efficiency was measured as > 70% by
visualization of GFP. Forty-eight hours after transfection, expression of exogenous and endogenous drebrin was examined by Western blot
analysis with antibodies to GFP or drebrin (Dbn). (B) Forty-eight hours after transfection, cells were switched to differentiation medium with or
without 5 μM BTP2 as indicated. Seventy-two hours later, cultures were fixed and immunostained for myosin heavy chain (MHC; red). GFP and
exogenous drebrin expression were visualized by direct fluorescence (green). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole
(blue). KM, KM-GFP; drebrin E (K270M, K271M)-GFP. (C) Quantification of the fusion index in cultures from (A). Values shown are means ± SD of
triplicate determinations. *P < 0.01 as compared to BTP2-treated GFP-expressing cultures.
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Page 9 of 13Figure 7 BTP2 does not block late stages of myoblast differentiation. (A) Experimental scheme outlining the treatment of C2C12 cells with
BTP2 and subsequent analysis. (B) Western blot analysis of C2C12 cultures in growth medium (G), at the time of transfer to differentiation
medium (DM) (time 0) or incubated in DM plus BTP2 from either time 0 or 60 hours and harvested at either 72 or 120 hours. (C) Cultures
parallel to those in part (B) were fixed and stained for myosin heavy chain (MHC; red) and 4’,6-diamidino-2-phenylindole (blue). (D)
Quantification of the total fusion index in cultures from part (C).* P < 0.05 as compared with dimethyl sulfoxide (DMSO) control at the same
time point. (E) Quantification of myotube formation. Values shown are means ± SD of triplicate determinations. *P < 0.05 as compared to the
DMSO control at the same time point in the graph above.
Mancini et al. Skeletal Muscle 2011, 1:36
http://www.skeletalmusclejournal.com/content/1/1/36
Page 10 of 13BTP2 treatment, drebrin function was not required after
60 hours in DM, supports the idea that regulation of
myogenin expression is likely involved with at least
some portion of drebrin’s actions in myogenesis. Consis-
tent with this notion, there is evidence to suggest that
proper regulation of cytoskeletal structures may be
important in muscle-specific gene expression. For exam-
ple, muscle-specific gene expression is hindered when
myoblasts are treated with the F-actin remodeling inhi-
bitor latrunculin B or depleted of the microtubule-
Figure 8 Drebrin localization in growing and differentiating C2C12 cells. (A) C2C12 cells in growth medium (GM) or differentiation medium
(DM) for 1 day (D1) were fixed and immunostained for endogenous drebrin (Dbn1; green) and F-actin (red). Arrows indicate areas of overlapping
enrichment for drebrin and F-actin in cell processes (GM) and at sites of cell-cell contact (D1). (B) C2C12 cells in DM for 3 days (D3) were fixed
and immunostained as in part (A). Arrows show areas of overlapping enrichment for drebrin and F-actin at the tips of myotubes (left panels)
and at sites of cell-cell contact between myotubes (right panels). (C) C2C12 cells were transfected with vectors encoding GFP or drebrin E-GFP.
Cells were fixed, and actin was visualized by staining with phalloidin (red). GFP and exogenous drebrin expression were visualized by direct
fluorescence (green). Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (blue). Arrows show enrichment for drebrin-GFP and F-actin.
The exposure time for cultures in GM was three times as long as it was for cultures in DM (1.14 seconds vs 300 to 400 milliseconds, respectively)
to visualize the lower levels of drebrin protein in cells in GM.
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Page 11 of 13binding protein EB1 [21,24]. Additionally, Gussoni and
colleagues [51] reported that C6ORF32, a cytoplasmic
protein induced during myoblast differentiation that
promotes filopodia formation, is important for expres-
sion of myogenin and MHC. Furthermore, depletion in
cultured mammalian myoblasts of factors specific for
myoblast fusion in Drosophila (for example, Dock1,
Brag2) not only blocks formation of multinucleated cells
but also decreases the percentage of cells that express
muscle-specific markers [21,52]. It seems logical that at
least some aspects of muscle-specific transcription and
myoblast fusion would be coordinately regulated via
cytoskeletal dynamics, and, if so, drebrin would be well-
placed to participate in such coordinated regulation.
Consistent with this likelihood, our findings indicate
that drebrin in myoblasts is enriched in cellular projec-
tions, cell cortices and regions of cell-cell contact, all
sites where we found F-actin was also concentrated.
Drebrin interacts with several other proteins that have
been implicated in myoblast differentiation and fusion.
For example, drebrin binds the microtubule plus-tip
binding protein EB3 in axonal growth cones. This inter-
action is important for growth cone formation and axo-
nal growth and provides a link between F-actin and
dynamic microtubules [30,33]. EB3 is important for
myoblast fusion, and its expression is induced during
myoblast differentiation with kinetics similar to Dbn1
induction [34]. Drebrin also binds to the scaffold protein
Homer [35]. Homer2b promotes signaling by the calci-
neurin/Nuclear Factor of Activated T Cells (NFAT)
pathway and enhances myoblast differentiation and
myotube formation [36]. NFAT family members regulate
several aspects of myogenesis [7]. Interestingly, the dreb-
rin inhibitor BTP2 was originally identified in a screen
for small-molecule antagonists of NFAT activity and
was subsequently shown to bind directly to drebrin [47].
In addition to their ability to regulate calcium signaling,
Homer proteins associate with Cdc42 [35], a small
GTPase involved in myoblast differentiation and fusion
[37,38]. Finally, drebrin binds to the cytoplasmic tail of
the chemokine receptor CXCR4 [40]. CXCR4 promotes
myoblast and myocyte migration [39]. Given the
plethora of drebrin interactions of potential relevance,
extensive structure-function studies are likely necessary
to identify the most important ones for drebrin’s actions
in myogenesis.
Conclusions
In this study, we identified Dbn1 as a gene induced dur-
ing myoblast differentiation in a p38 MAPK-dependent
manner. Dbn1 encodes drebrin, an actin-binding protein
that localizes to cellular extensions, cell cortices and
sites of cell-cell contact. Inhibition of drebrin function,
either by RNAi-mediated depletion or by the small-
molecule inhibitor BTP2, reveals a role for drebrin in
myogenic differentiation.
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